Skip to main content
Medicure Inc logo

Medicure Inc — Investor Relations & Filings

Ticker · MPH ISIN · CA58469E4085 LEI · 9845007T999BF377B627 TSXV Manufacturing
Open in API
Filings indexed 293 across all filing types
Latest filing 2024-08-14 Regulatory Filings
Country CA Canada
Listing TSXV MPH

About Medicure Inc

https://www.medicure.com/

Medicure Inc. is a value-based pharmaceutical company specializing in the research, clinical development, and commercialization of human therapeutics. The company is primarily focused on developing and commercializing innovative and affordable medicines within the cardiovascular therapeutic area. Medicure's core mission is to serve patients by delivering safe and efficacious life-changing medicines, with a strategic focus on the U.S. market. It aims to offer a growing portfolio of products and services, ensuring patient access to necessary care.

Recent filings

Filing Released Lang Actions
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 100% confidence The document is a certification by the CEO of Medicure Inc. regarding the interim financial report and interim MD&A for the period ended June 30, 2024. It is a Form 52-109FV2 Certification of Interim Filings for a Venture Issuer, which is a regulatory attestation confirming the accuracy and fair presentation of the interim filings. The document does not contain the actual interim financial statements or substantive financial data but is a certification letter. According to the Certification Rule, such officer certifications should be classified as Regulatory Filings (RNS) rather than as the interim report itself (IR). The document length is short (2993 characters), and it is clearly a certification, not the report or announcement of a report publication. Therefore, the correct classification is Regulatory Filings (RNS).
2024-08-14 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 100% confidence The document is a FORM 52-109FV2 Certification of Interim Filings Venture Issuer Basic Certificate, signed by the CFO, certifying the review and fair presentation of the interim financial report and interim MD&A for the period ended June 30, 2024. It explicitly states it is a certification letter and does not contain the actual interim financial data or analysis itself. According to the CERTIFICATION RULE, such officer certifications or attestations, even if referencing interim reports, should be classified as Regulatory Filings (RNS) rather than the interim report itself. The document length is under 5,000 characters and is a certification letter, not the report or announcement of a report. Therefore, the correct classification is Regulatory Filings (RNS).
2024-08-14 English
Interim financial statements/report – English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing that Buhler Industries has entered into a new $45 million credit facility with Farm Credit Canada. It details the terms of the financing, including a mortgage and revolving loan, and mentions ongoing negotiations for additional credit facilities. There is no detailed financial data, comprehensive financial statements, or management discussion of results. The document is focused on financing activities and capital structure updates. It is not an annual or interim report, earnings release, or regulatory filing. The length is under 5,000 characters and it is a clear announcement of financing activity. Therefore, the document fits best under the category 'Capital/Financing Update' (CAP).
2024-08-14 English
Interim MD&A - English.pdf
Management Reports Classification · 95% confidence The document is titled 'Management's Discussion and Analysis for the three and six months ended June 30, 2024' and contains detailed discussion of the company's business, financial performance, forward-looking statements, and operational overview. It references the interim financial statements for the three and six months ended June 30, 2024, and the annual report for the year ended December 31, 2023. The content is substantive and includes financial and operational analysis, consistent with a Management Discussion and Analysis (MD&A) report. It is not merely an announcement or a certification, nor is it a full annual report or earnings release. Therefore, the document fits the category of Management Reports (MDA).
2024-08-14 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing the signing of an asset purchase agreement between Medicure Inc. and CanAm Bioresearch Inc. for the acquisition of intellectual property related to new chemical entities. It details the terms of the agreement, milestone payments, and conditions for closing. The document includes forward-looking statements and legal disclaimers typical of a corporate announcement. There are no financial statements, quarterly or annual results, nor is this a transcript or regulatory filing of financial data. It is not a report but an announcement of a transaction and related corporate update. Therefore, it fits best under Capital/Financing Update (CAP) as it relates to a significant corporate transaction involving asset acquisition and potential future payments tied to development milestones.
2024-06-24 English
News release - English.pdf
Regulatory Filings
2024-05-28 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.